CIDP May Be a Complication of Cilta-Cel Therapy Researchers presented the case of 2 patients who developed CIDP after CAR-T cell therapy for multiple myeloma.

Researchers from Germany presented the case of 2 patients who developed #CIDP following treatment with ciltacabtagene-autoleucel (#CiltaCel), a chimeric antigen receptor T (CAR-T) cell therapy for #MultipleMyeloma.

Read here: https://bit.ly/3JBZesQ

#RareDisease #RareSky #MedSky

Hematology Weekly News – September 8th 2025 🔬🩸 Hematology Updates: Functional Cure Signals, Head-to-Head CAR-T, Outpatient Bispecifics, BTK Approval, and More From five-year MRD-negative remissions in myeloma […] The post Hematology Weekly News – September 8th 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Hematology Weekly News – September 8th 2025 #News #AML #Carvykti #CellCentric #Ciltacel Comment below!

Cilta-Cel Shows Superior Efficacy, Survival Over Ide-Cel, but Higher Toxicity in R/R MM | ASH Clinical News | American Society of Hematology

In patients with heavily pretreated R/R #MultipleMyeloma #MMsm, #ciltacel was found to be associated with better treatment responses compared with #idecel but had higher rates of toxicity, such as CRS: ashpublications.org/ashclinicaln...
#HemeSky #HemeOnc

Blood cancer patients face treatment access disparity - PharmaTimes New research highlights NHS approval gap compared to other cancers

#healthinequalities #Bloodcancer #Bloodcancerpatients #Bloodcancertreatment #BloodCancerAlliance #bloodcancertreatments #NICEapproval #pharmaceuticalcompanies #NICEappraisals #patientoutcomes #CARTtherapy #CiltaCel #myeloma #NICEappraisalprocesses #patientaccess
pharmatimes.com/news/blood-c...